{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:16:13Z","timestamp":1761920173235,"version":"3.41.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T00:00:00Z","timestamp":1468281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Biogen GmbH, Ismaning"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12883-016-0625-0","type":"journal-article","created":{"date-parts":[[2016,7,12]],"date-time":"2016-07-12T10:33:40Z","timestamp":1468319620000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Design of TRUST, a non-interventional, multicenter, 3-year prospective study investigating an integrated patient management approach in patients with relapsing-remitting multiple sclerosis treated with natalizumab"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8799-8202","authenticated-orcid":false,"given":"Tjalf","family":"Ziemssen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Achim","family":"Gass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Wuerfel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonios","family":"Bayas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Tackenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Limmroth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Linker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"M\u00e4urer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Stangel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Meergans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olof","family":"Harlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans-Peter","family":"Hartung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,7,12]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1586\/14737175.4.4.571","volume":"4","author":"RA Rudick","year":"2004","unstructured":"Rudick RA, Sandrock A. Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004;4:571\u201380.","journal-title":"Expert Rev Neurother"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899\u2013910.","journal-title":"N Engl J Med"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.mayocp.2013.11.002","volume":"89","author":"DM Wingerchuk","year":"2014","unstructured":"Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc. 2014;89:225\u201340.","journal-title":"Mayo Clin Proc"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","volume":"85","author":"H Butzkueven","year":"2014","unstructured":"Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, Patel RN, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry. 2014;85:1190\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"625_CR5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ana.24339","volume":"77","author":"T Kalincik","year":"2015","unstructured":"Kalincik T, Horakova D, Spelman T, Jokubaitis V, Trojano M, Lugaresi A, MSBase Study Group, et al. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis. Ann Neurol. 2015;77:425\u201335.","journal-title":"Ann Neurol"},{"key":"625_CR6","unstructured":"Biogen. Data on file: https:\/\/medinfo.biogen.com . Accessed: 01 Dec 2015."},{"key":"625_CR7","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","volume":"73","author":"PL McCormack","year":"2013","unstructured":"McCormack PL. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis. Drugs. 2013;73:1463\u201381.","journal-title":"Drugs"},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3389\/fimmu.2015.00159","volume":"6","author":"MC Monaco","year":"2015","unstructured":"Monaco MC, Major EO. Immune system involvement in the pathogenesis of JC virus induced PML: What is learned from studies of patients with underlying diseases and therapies as risk factors. Front Immunol. 2015;6:159.","journal-title":"Front Immunol"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMoa051782","volume":"353","author":"BK Kleinschmidt-DeMasters","year":"2005","unstructured":"Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med. 2005;353:369\u201374.","journal-title":"N Engl J Med"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMoa051847","volume":"353","author":"A Langer-Gould","year":"2005","unstructured":"Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375\u201381.","journal-title":"N Engl J Med"},{"key":"625_CR11","unstructured":"Food and Drug Administration [FDA Drug Safety Communication]. FDA warns about case of rare brain infection PML with MS drug Tecfidera (dimethyl fumarate); 25 Nov 2014. www.fda.gov\/drugs\/drugsafety\/ucm424625.htm . Accessed: 01 Oct 2015."},{"key":"625_CR12","unstructured":"Food and Drug Administration [FDA Drug Safety Communication]. FDA warns about cases of rare brain infection with MS drug Gilenya (fingolimod) in two patients with no prior exposure to immunosuppressant drugs; 4 Aug 2015. www.fda.gov\/drugs\/drugsafety\/ucm456919.htm . Accessed: 01 Oct 2015."},{"key":"625_CR13","unstructured":"Biogen. Data on file: https:\/\/medinfo.biogen.com . Accessed: 01 Dec 2015"},{"key":"625_CR14","unstructured":"European Medicines Agency (EMA) 2016; EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/referrals\/Tysabri\/human_referral_prac_000049.jsp&mid=WC0b01ac05805c516f . Accessed 30 May 2016."},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1002\/ana.24286","volume":"76","author":"T Plavina","year":"2014","unstructured":"Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, et al. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:802\u201312.","journal-title":"Ann Neurol"},{"key":"625_CR16","doi-asserted-by":"publisher","first-page":"668","DOI":"10.3389\/fimmu.2014.00668","volume":"5","author":"C Antoniol","year":"2015","unstructured":"Antoniol C, Stankoff B. Immunological markers for PML prediction in MS patients treated with natalizumab. Front Immunol. 2015;5:668.","journal-title":"Front Immunol"},{"key":"625_CR17","doi-asserted-by":"crossref","unstructured":"Schwab N, Schneider-Hohendorf T, Pignolet B, Spadaro M, G\u00f6rlich D, Meinl I, et al. PML risk stratification using anti-JCV antibody index and L-selectin. Mult Scler. 2015 [Epub ahead of print]","DOI":"10.1177\/1352458515607651"},{"key":"625_CR18","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1212\/WNL.0b013e3182a351fb","volume":"81","author":"N Schwab","year":"2013","unstructured":"Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, G\u00f6bel K, Windhagen S, et al. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81:865\u201371.","journal-title":"Neurology"},{"key":"625_CR19","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12974-015-0365-x","volume":"12","author":"M Spadaro","year":"2015","unstructured":"Spadaro M, Caldano M, Marnetto F, Lugaresi A, Bertolotto A. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells. J Neuroinflammation. 2015;12:146.","journal-title":"J Neuroinflammation"},{"key":"625_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1212\/WNL.0000000000002314","volume":"86","author":"L Lieberman","year":"2016","unstructured":"Lieberman L, Zeng W, Singh C, Wang W, Otipoby K, Loh C, et al. CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients. Neurology. 2016;86:375\u201381.","journal-title":"Neurology"},{"key":"625_CR21","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/ana.24345","volume":"77","author":"LM Villar","year":"2015","unstructured":"Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, et al. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. Ann Neurol. 2015;77:447\u201357.","journal-title":"Ann Neurol"},{"key":"625_CR22","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80:1430\u20138.","journal-title":"Neurology"},{"key":"625_CR23","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/acn3.114","volume":"1","author":"T Dong-Si","year":"2014","unstructured":"Dong-Si T, Richman S, Wattjes MP, Wenten M, Gheuens S, Philip J, et al. Outcome and survival of asymptomatic PML in natalizumab-treated MS patients. Ann Clin Transl Neurol. 2014;1:755\u201364.","journal-title":"Ann Clin Transl Neurol"},{"key":"625_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrneurol.2015.157","volume":"11","author":"MP Wattjes","year":"2015","unstructured":"Wattjes MP, Rovira A, Miller D, Yousry TA, Sormani MP, de Stefano MP, et al. MAGNIMS study group. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597\u2013606.","journal-title":"Nat Rev Neurol"},{"key":"625_CR25","unstructured":"Papeix C, et al. Confavreux on behalf of the TYSEDMUS Group. Natalizumab discontinuation in clinical practice: a systematic observational study from the national TYSEDMUS cohort of 577 multiple sclerosis patients treated with natalizumab in France. Presented at the Congress of European Committee for Treatment and Research in Multiple Sclerosis 2012. Abstract."},{"key":"625_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","volume":"85","author":"L Kappos","year":"2015","unstructured":"Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, TOFINGO study group, et al. Switching from natalizumab to fingolimod: a randomized, placebo-controlled study in RRMS. Neurology. 2015;85:29\u201339.","journal-title":"Neurology"},{"key":"625_CR27","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12974-016-0635-2","volume":"13","author":"T Sehr","year":"2016","unstructured":"Sehr T, Proschmann U, Thomas K, Marggraf M, Straube E, Reichmann H, Chan A, Ziemssen T. New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies. Journal of Neuroinflammation. 2016;13:164.","journal-title":"Journal of Neuroinflammation."},{"key":"625_CR28","doi-asserted-by":"publisher","unstructured":"Ziemssen T, Hillert J, Butzkueven H. The importance of collecting structured clinical informationon multiple sclerosis. BMC Medicine.2016;14:81. DOI 10.1186\/s12916-016-0627-1","DOI":"10.1186\/s12916-016-0627-1"},{"key":"625_CR29","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/jnnp-2016-315106.113","volume":"87","author":"C McGuigan","year":"2016","unstructured":"McGuigan C, Craner M, Guadagno J, Kapoor R, Mazibrada G, Molyneux P, et al. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group. J Neurol Neurosurg Psychiatry. 2016;87:117\u201325.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"Suppl 1","key":"625_CR30","doi-asserted-by":"publisher","first-page":"S61","DOI":"10.1007\/s00702-013-1041-x","volume":"120","author":"T Ziemssen","year":"2013","unstructured":"Ziemssen T, Kempcke R, Eulitz M, Gro\u00dfmann L, Suhrbier A, Thomas K, et al. Multiple sclerosis documentation system (MSDS): moving from documentation to management of MS patients. J Neural Transm. 2013;120 Suppl 1:S61\u20136.","journal-title":"J Neural Transm"},{"key":"625_CR31","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1001\/jamaneurol.2013.6240","volume":"71","author":"M Cohen","year":"2014","unstructured":"Cohen M, Maillart E, Tourbah A, De S\u00e8ze J, Vukusic S, Brassat D, et al. Club Francophone de la Scl\u00e9rose en Plaques Investigators. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 2014;71:436\u201341.","journal-title":"JAMA Neurol"},{"key":"625_CR32","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ana.24153","volume":"76","author":"C Warnke","year":"2014","unstructured":"Warnke C, von Geldern G, Markwerth P, Dehmel T, Hoepner R, Gold R, et al. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2014;76:792\u2013801.","journal-title":"Ann Neurol"},{"key":"625_CR33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","volume":"69","author":"CH Polman","year":"2011","unstructured":"Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69:292\u2013302.","journal-title":"Ann Neurol"},{"key":"625_CR34","unstructured":"Bentama D. Competence Network MS: REGIMS \u2013 an immunotherapy registry aiming at the improvement of drug safety in multiple sclerosis therapy. Presented at the Congress of the German Neurological Society (DGN) 2013. Poster [in German]."},{"key":"625_CR35","unstructured":"German Federal Institute for Drugs and Medical Devices (BfArM) 2010; Recommendations of the German Federal Institute for Drugs and Medical Devices and the Paul Ehrlich Institute for planning, conduct and analysis of non-interventional studies [document in German]. http:\/\/www.bfarm.de\/SharedDocs\/Bekanntmachungen\/DE\/Arzneimittel\/klinPr\/bm-KlinPr-20100707-NichtinterventePr-pdf.pdf?__blob=publicationFile&v=6 . Accessed: 01 Oct 2015."},{"key":"625_CR36","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1016\/j.jclinepi.2011.07.010","volume":"64","author":"V Gallo","year":"2011","unstructured":"Gallo V, Egger M, McCormack V, Farmer PB, Loannidis JP, Kirsch-Volders M, et al. STrengthening the Reporting of Observational studies in Epidemiology\u2013Molecular Epidemiology STROBE-ME: an extension of the STROBE statement. J Clin Epidemiol. 2011;64:1350\u201363.","journal-title":"J Clin Epidemiol"},{"key":"625_CR37","unstructured":"FSA-Kodex zur Zusammenarbeit mit Fachkreisen. Abschnitt 4, \u00a719: Nichtinterventionelle Studien mit zugelassenen Arzneimitteln. www.fsa-pharma.de\/verhaltenskodizes\/fachkreise . Accessed 01 Oct 2015."},{"key":"625_CR38","unstructured":"International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals; updated Dec 2015. http:\/\/www.icmje.org\/icmje-recommendations.pdf . Accessed 07 Mar 2016."},{"key":"625_CR39","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1212\/WNL.0000000000000355","volume":"82","author":"RJ Fox","year":"2014","unstructured":"Fox RJ, Cree BA, De S\u00e8ze J, Gold R, Hartung HP, Jeffery D, et al. RESTORE. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82:1491\u20138.","journal-title":"Neurology"},{"key":"625_CR40","doi-asserted-by":"crossref","unstructured":"Cohan S, Moses H, Calkwood J, LaGanke C, Tornatore C, Smoot KE, et al. Real-world clinical outcomes in relapsing-remitting multiple sclerosis patients who switch from natalizumab to delayed-release dimethyl fumarate: preliminary analysis of a multicenter, retrospective, observational study (STRATEGY). Presented at American Academy of Neurology. April 18\u201325, 2015; Washington, DC. Abstract P3.293.","DOI":"10.1212\/WNL.84.14_supplement.P3.293"},{"key":"625_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cei.12206","volume":"175","author":"PS Rommer","year":"2014","unstructured":"Rommer PS, Zettl UK, Kieseier B, Hartung HP, Menge T, Frohman E, et al. Requirement for safety monitoring for approved multiple sclerosis therapies: an overview. Clin Exp Immunol. 2014;175:397\u2013407.","journal-title":"Clin Exp Immunol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12883-016-0625-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0625-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-016-0625-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:42:12Z","timestamp":1748997732000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-016-0625-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1186\/s12883-016-0625-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"type":"electronic","value":"1471-2377"}],"subject":[],"published":{"date-parts":[[2016,7,12]]},"article-number":"98"}}